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Standardized and Individualized Parenteral Nutrition
Mixtures in a Pediatric Home Parenteral Nutrition Population
Sjoerd C.J. Nagelkerke, Cora F. Jonkers-Schuitema, yWendy L.M. Kastelijn,
zAnne-Loes E. Gerards, Marc A. Benninga, yBarbara A.E. de Koning, and Merit M. Tabbers
ABSTRACT
Objectives: Studies evaluating efficacy or safety of standardized parenteral
nutrition (PN) versus individualized PN are lacking. We aimed to assess
effects on growth and safety of standardized PN compared with individual-
ized PN in our Home PN group.
Methods:Descriptive cohort study in Dutch children on Home PN, in which
standardized PN was compared with individualized PN. Both groups
received similar micronutrient-supplementation. Primary outcome was
growth over 2 years, secondary outcomes were electrolyte disturbances
and biochemical abnormalities. Additionally, patients were matched for age
to control for potential confounding characteristics.
Results: Fifty patients (50% girls, median age 6.5 years) were included, 16
(32%) received standardized PN mixtures. Age (11 vs 5 years), gestational
age (39.2 vs 36.2 weeks) and PN duration (97 vs 39 months) were
significantly higher in the group receiving standardized PN (P: 0.001;
0.027; 0.013 respectively). The standardized PN group showed an increase
in weight-for-age (WFA), compared with a decrease in the individualized
PN group (þ0.38 SD vs 0.55 SD, P: 0.003). Electrolyte disturbances and
biochemical abnormalities did not differ. After matching for age, resulting in
comparable groups, no significant differences were demonstrated in WFA,
height-for-age, or weight-for-height SD change.
Conclusions: InchildrenwithchronicIF,over2,5yearsofage, standardizedPN
mixturesshowacomparableeffectonweight,height,andweight forheightwhen
compared with individualized PN mixtures. Also, standardized PN mixtures
(with addedmicronutrients) seem noninferior to individualized PNmixtures in
terms of electrolyte disturbances and basic biochemical abnormalities. Larger
studiesareneededtoconfirmtheseconclusions.Trial Registration:Academical
Medical Center medical ethics committee number W18_079 #18.103.
Key Words: electrolytes, growth, home parenteral nutrition, pediatric
intestinal failure, standardized mixtures
(JPGN 2020;70: 269–274)
I ntestinal failure (IF) is defined as a critical reduction of func-tional gut mass below the minimum necessary for adequate
digestion and absorption to satisfy body nutrient and fluid require-
ments for adequate growth and development in children (1,2).
Causes of IF in children consist of short bowel syndrome (SBS),
intestinal neuromuscular motility, and intrinsic epithelial disorders
(3–5). Children with IF are (partly) dependent on parenteral nutri-
tion (PN) to achieve adequate growth, and fluid and electrolyte
What Is Known
 Current guidelines on pediatric parenteral nutrition
conclude that standardized parenteral nutrition
mixtures are not suitable for children with chronic
intestinal failure on home parenteral nutrition.
 Studies evaluating efficacy or safety of standardized
parenteral nutrition are lacking.
What Is New
 In children over 2.5 years of age with chronic intesti-
nal failure and stable nutritional need, standardized
parenteral nutrition mixtures show comparable
growth (weight, height, andweight for height) when
compared with individualized parenteral nutrition
mixtures.
 Standardized parenteral nutrition mixtures are at
least noninferior to individualized parenteral nutri-
tion mixtures in terms of electrolyte disturbances and
basic biochemical abnormalities in a home parenteral
nutrition cohort. As both groups received similar
amounts of micronutrients, micronutrients were
not analyzed.
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homeostasis (1). Goal is to achieve intestinal autonomy, meaning
there is no longer need for Home PN administration (6). Prevalence
of Home PN use varies across studies, ranging from 9.6 to 14.1
children per million (7,8).
In children, PN requirements vary, depending on age,
weight, nutritional and hydration status, underlying disease, daily
activity level, and environmental conditions. Regarding PN, both
standardized formulations compounded by pharmaceutical com-
panies and individualized formulations compounded by a phar-
macy are available. According to the recently updated Guidelines
on Pediatric PN uncritical use of standardized formulations
particularly over longer periods of time, may be less than optimal
for growth and development (9,10). However, data are lacking
supporting this conclusion. Apart from possibly not being optimal
for growth and development, concerns can also be raised about
potential electrolyte imbalances when standardized PN mixtures
are prescribed. In contrast, possible advantages of standardized
PN solutions could be a reduction in costs and a longer shelf life
than individualized PN solutions. A longer shelf life could, for
example, enable patients and parents to go on vacations for
longer duration.
As all published studies on the effects of standardized PN
mixtures have been performed in hospitalized children, we aimed to
investigate the effects and safety of standardized and individualized
PN on growth in a pediatric Home PN population.
METHODS
Subjects
All children (0–18 years of age) receiving Home PN from
2 Dutch dedicated pediatric Home PN centers visiting the
outpatient clinic between June 2017 and July 2018 were eligible
for inclusion (Emma Children’s Hospital/Amsterdam University
Medical Center and Sophia Children’s Hospital/Erasmus Medical
Center). Patients were excluded if they received PN for less than
6 months.
Measurements
Study data were collected via chart review, including demo-
graphic and clinical patient characteristics (including the number of
central line- associated bloodstream infections (CLABSI), number
of hospital admissions and the frequency of comorbidities). Bowel
characteristics, nutritional data, growth measurements and labora-
tory data were noted. Date of inclusion was defined as date of visit at
the Home PN-outpatient clinic in the period between June 2017 and
July 2018. When 2 or more outpatient visits were made in this
period, the visit with complete laboratory data was included.
Primary outcome measure was growth (Weight-For-Age [WFA],
Height-For-Age [HFA] and Weight For Height (WFH)] after 24
months. Secondary outcome measures were electrolyte distur-
bances and biochemical abnormalities including liver function.
All outcome measures were assessed for the period patient received
either standardized or individualized PN.
Growth
Weight and height were measured using standard measuring
equipment. With the Growth Analyzer VE version 1.5.1 (Growth
Analyzer BV, The Netherlands), using up-to-date Dutch national
reference standards, sex- and age-adjusted standard deviation scores
(SDS) were obtained for WFA, HFA, and WFH (11). Measurements
were retrieved at the date of inclusion and 6, 12, and 24 months
before date of inclusion. Growth was assessed by calculating the
difference in age-adjusted SDS between date of inclusion and
previous measurement at minus 6, 12, and 24 months. This differ-
ence indicated a change in growth chart position.
Parenteral Nutrition Mixtures and Oral/enteral
Intake
Patients were either coded as receiver of standardized
(commercially available bag with additions) or individualized
PN mixtures when they received this type of mixture for at least
6 months at inclusion. If patients switched from individualized PN
to standardized PN during the study period, or vice versa, growth
was only assessed from the moment of the switch till the date of
inclusion. In our practice, a single bag of PN per day is provided in
order to lighten the burden of care on parents and prevent com-
pounding errors. Patients were prescribed standardized PN when
nutritional need was stable over at least 3 months and the compo-
sition of an available mixture met their nutritional need. Fluids and
electrolytes were added to the standardized PN if this did not
exceed the limitations imposed by the manufacturer. When
patient’s nutritional need was not met by the available mixtures,
for example, because of intestinal losses requiring the compensa-
tion of large volumes of fluids and/or electrolytes, individualized
PN was prescribed. Individualized PN mixtures were compounded
by the hospital pharmacy. Compounding of these mixtures is done
under stringent conditions and the composition is frequently
checked. Different standardized PN mixtures were prescribed to
patients (Table 1). If patients received standardized PN mixtures,
parents added all micronutrient additions before infusion. Both
groups received the same amount of vitamin and trace elements per
bag, therefore, micronutrient levels were not analyzed. Composi-
tion of PN was recorded for all mixtures as well as the number of
PN days per week. Amount of infused lipids (all patients received
mixed lipid preparations), amino acids, and carbohydrates per
week was calculated and recorded as grams/day. Furthermore, if
patients received enteral nutrition (EN), the amount of macronu-
trients was recorded as grams/day. Finally, it was noted if patients
were partially fed orally. Detailed and reliable information regard-
ing oral intake is not available because of the retrospective char-
acter of this study. Furthermore, it is unknown to which degree
enteral provided nutrients are absorbed. The prescribed PN and EN
reflect the response of the treating physician to the patient’s weight
gain and growth over time.
All patients received Taurolidine locks for the prevention
of CLABSI.
TABLE 1. Types of prescribed standardized parenteral nutrition for-
mula
PN brand, manufacturer
Number of prescriptions
(number of exclusive
prescriptions

)
Smofkabiven Central, Fresenius Kabi 6 (4)
Aminomix 1 Novum, Fresenius Kabi 3 (0)
Olimel N5E, Baxter 1 (1)
Olimel N7E, Baxter 5 (5)
Olimel N9E, Baxter 2 (1)
Numeta G16%E, Baxter 1 (1)
Numeta G19%E, Baxter 1 (1)
PN ¼ parenteral nutrition.
Three patients received both Aminomix 1 Novum (without lipids) and
either Smofkabiven Central or Olimel N9E (with lipids). If patients solely
received 1 mixture, they were coded as exclusive prescription.
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Patients’ nutritional need at time of inclusion was calculated
according to the hospital’s protocol by a dietician, using the
Schofield formula and adding the increased energy expenditure
associated with activity, disease state and growth (12,13).
Biochemical Values
Serum glucose, triglyceride, and electrolyte concentrations at
time of inclusion were studied. Liver function (albumin, prothrom-
bin time and bilirubin [total and conjugated]) and liver enzymes
(aspartate aminotransferase [AST], alanine aminotransferase
[ALT], g-glutamyl transferase [GGT] and alkaline phosphatase
[AP]) were noted. Additionally, we recorded whether patients were
admitted because of electrolyte abnormalities in the 24 months
previous to date of inclusion.
Statistical Analysis
Statistical analyses were performed using SPSS version
24.0.0.1 (IBM corporation, Armonk NY). Continuous data are sum-
marized as median and interquartile range (IQR), categorical data are
presented as frequencies and percentages. Mann-Whitney U test and
Fisher Exact test were used to assess differences between patients
receiving standardized or individualized PN mixtures for continuous
data and categorical data, respectively. A 2 sided P value 0.05 was
considered as statistically significant. As an additional analysis, to
compensate for differences in baseline characteristics, one-to-one
case control matching on age was performed leading to an even
distribution of potential confounding baseline characteristics.
As differences between nutritional need and caloric intake
could be a possible confounder for weight gain, this difference was
calculated. For both groups, Kendall tau was used to investigate the
correlation of this difference with weight gain.
The Institutional Review Board/Independent Ethics Com-
mittee of the Academic Medical Center declared that this study did
not have to be reviewed by a medical ethics board according to
Dutch Law on Medical Research with Humans (WMO).
RESULTS
Patient Characteristics
In total, 56 patients received Home PN. Of these, 50 patients
(50% girls) were included for analysis, of whom 16 (32%) received
standardized PN mixtures. Six patients were not included because
PN was used less than 6 months. Median age at inclusion was 6.5
years (IQR: 3.5–10.5, minimum 0.5 years) and median PN duration
was 62 months (IQR: 18–99). Patient characteristics are shown in
Table 2. Age, gestational age (GA), and PN duration were
TABLE 2. Demographic patient characteristics
Before matching After matching
Standard (n¼ 16) Individualized (n¼ 34) P Standard (n¼ 10) Individualized (n¼ 10) P
Sex (female) 8 (50) 17 (50) 1.000

7 (70) 5 (50) 0.650

Age (years) 11 (8.5–14) 5 (2.5–7.5) <— 0.001
y 9 (5 –11) 8 (6–11) 0.796y
Gestational age (weeks) 39.2 (35.3–41) 36.2 (34.3–37.8) 0.027y 38.8 (34.9–40.3) 36.2 (34.5–38.8) 0.315y
Gestational age <37.0 weeks 4 (25) 22 (65) 0.015

2 (20) 7 (70) 0.070y
Birth weight (SD-score) 0.07 (0.88 to 0.29) 0.32 (1.51–.54) 0.793y 0.06 (1.13–.14) 0.11 (1.04–.63) 0.661y
Underlying disease 0.601

0.307

Short bowel syndrome 7 (44) 15 (44) 5 (50) 3 (30)
Small bowel length (cm) 43 (26–54) 32 (15–60) 0.620y 45 (35–57) 8 (0–35) 0.063y
Bowel lengthening procedure 3 (19) 6 (18) 1.000

3 (30) 2 (20) 1.000

Motility disorder 7 (44) 11 (32) 4 (40) 5 (50)
Microvillus Inclusion disease 0 4 (12) 0 2 (20)
Other 2 (13) 4 (12) 1 (10) 0
Ileocecal valve in situ 8 (50) 25 (74) 0.121

4 (40) 6 (60) 0.656

Colon in situ 9 (56) 26 (77) 0.191

5 (50) 7 (70) 0.650

Comorbidityz 7 (44) 19 (59) 0.366 4 (40) 8 (80) 0.170
CLABSI (/1000 PNdays)§ 2.7 (1.4–5.1) 2.7 (1.4–4.8) 0.497y 2.7 (1.4–4.1) 2.7 (1.4–4.7) 0.968y
Hospital§ Admission
(/1000 PNdays)
2.1 (0–5.1) 1.4 (1–4.1) 0.890y 2.7 (0–4.1) 2.7 (1.4–4.1) 0.877y
Hospital Admissionjj (days) 9,5 (0–23.5) 8 (1.5–46.25) 0.563y 9.5 (0–26) 7.5 (3–17) 0.879y
PN duration (months) 97 (40–134) 39 (13–80) 0.013y 66 (26–113) 81 (25–137) 0.631y
Total PN Infusion (kCal/day) 1213 (1057–1471) 1125 (765–1372) 0.417y 1163 (524–1235) 1500 (959–1902) 0.143y
Days PN infusion at inclusion
(/week)§
7 (4–7) 7 (7–7) 0.002y 7 (4–7) 7 (7–7) 0.247y
Days PN infusion at T minus
24 months (/week)§
7 (5–7) 7 (7–7) 0.001y 7 (5–7) 7 (7–7) 0.143y
Days PN fat infusion at inclusion
(/week)§
5.5 (3–7) 5 (4–7) 0.741y 5 (2–7) 7 (4–7) 0.247y
Days PN fat infusion at T minus
24 months (/week)§
5.5 (3–7) 5 (4–7) 0.741y 5 (2–7) 7 (4–7) 0.247y
ECH/AUMC 11 (69) 24 (71) 1.000

7 (70) 10 (100) 0.211

All continuous data are presented as median (interquartile range), all categorical data is presented as n (%). AUMC¼AmsterdamUniversityMedical Centre;
CLABSI ¼ central line-associated bloodstream infection; ECH ¼ Emma Children’s Hospital; PN ¼ parenteral nutrition; SD ¼ standard deviation.
Fisher exact test was used to determine P value.
yMann-Whitney U test was used to determine P value.
zComorbidity defined as any disease other than underlying disease or PN-associated complication, such as intestinal failure associated-liver disease or
CLABSI.
§Number of.
jjDuring study period of 24 months.
Bold indicates a statistically significant difference between groups.
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significantly higher in the group receiving standardized PN (P:
0.001; 0.027; 0.013, respectively). The amount of PN infusions
per week was significantly lower in the standardized group (P:
0.002).
Growth
After 24 months, median change in WFA SDS in the
standardized PN group was þ0.38 SD (0.34 to 0.80), whereas
in the individualized PN group, a median decrease inWFA SDSwas
seen: 0.55 SD (1.11 to 0.07). The difference between these
groups reached statistical significance (P: 0.003). No statistical
differences at 24 months were seen regarding change in HFA SDS
or change in WFH SDS between the 2 groups (Table 3).
At all time points, WFA, HFA, and WFH did not signifi-
cantly differ between the groups (Supplemental Table 1, Supple-
mental Digital Content, http://links.lww.com/MPG/B729).
Intake
Six patients received total PN without any oral or enteral
intake, 1 (6%) in the standardized PN group versus 5 (15%) in the
individualized PN group (P: 0.65). In the standardized PN group,
19% (3/16) received EN compared with 38% (13/34) in the
individualized PN group (P: 0.218). As stated in the ‘‘Method
section’’, reliable data on amount of oral intake was not available.
Difference in nutritional need and caloric provision of enteral
and parenteral nutrition was calculated for both groups. The stan-
dardized PN group showed a median deficit of 17 calories/kg/day
(20 to 11). This was significantly different compared with the
individualized PN group where a deficit of 4 calories/kg/day per day
was observed (15 to 6, P: 0.029).
No significant relationship between this calculated differ-
ence and change in WFA SDS was seen in both groups:
rt¼0.121, P: 0.583 for the standardized PN group and
rt¼ 0.148, P: 0.363 for the individualized PN group.
Biochemical Values
No statistical differences in abnormal values for sodium
(Na), potassium (K), magnesium (Mg), calcium (Ca), and phos-
phorus (P) were observed between the 2 groups (Table 4). Also, no
statistical differences in abnormal liver tests were found between
both groups. Median total and conjugated bilirubin were 6.0mmol/L
(5.0–13.0) and 4.0mmol/L (2.3–6.0), respectively in the standard-
ized PN group and 5.0mmol/L (4.0–9.0) and 3.0mmol/L (2.0–4.0),
respectively in the individualized PN group. Both total and conju-
gated bilirubin concentrations did not statistically differ between
both groups (P: 0.473 and P: 0.662, respectively). Neither hyper-
glycemia (defined as 6.1mmol/L) nor hypertriglyceridemia
(2.1mmol/L) were seen in this cohort. No child was admitted
because of abnormal electrolyte concentrations.
Age-matched Cohort
Twenty patients were included for analysis after matching for
age. Median age of these 20 patients at inclusion was 9 years (IQR:
6–11, minimum 2.5 years) and median PN duration was 75 months
TABLE 3. Median change in standard deviation score over 6, 12, and 24 months
Before matching After matching
Standard n Individualized n P Standard n Individualized n P
Weight 6 months 0.07 (0.01 to 0.30) 15 0.02 (0.28 to 0.63) 32 0.592 0.19 (0.01 to 0.50) 10 0.19 (0.16 to 0.52) 10 0.842
12 months 0.16 (0.04 to 0.46) 15 0.19 (0.59 to 0.30) 25 0.047 0.16 (0.04 to 0.46) 10 0.22 (0.17 to 0.47) 10 0.721
24 months 0.38 (0.34 to 0.80) 12 0.55 (1.11 to 0.07) 20 0.003 0.80 (0.12 to 1.40) 10 0.42 (1.17 to 0.26) 10 0.051
Height 6 months 0.04 (0.09 to 0.22) 15 0.07 (0.33 to 0.23) 30 0.700 0.08 (0.31 to 0.16) 10 0.26 (0.40 to 0.01) 10 0.277
12 months 0.11 (0.28 to 0.53) 15 0.23 (0.39 to 0.14) 25 0.410 0.21 (0.45 to 0.06) 9 0.45 (0.70 to 0.06) 9 0.234
24 months 0.15 (0.65 to 0.39) 12 0.30 (0.86 to 0.35) 20 0.580 0.24 (0.79 to 0.05) 9 0.78 (0.89 to 0.12) 9 0.445
Weight for
height
6 months 0.12 (0.19 to 0.58) 15 0.16 (0.34 to 0.73) 30 0.819 0.40 (0.05 to 0.66) 10 0.35 (0.31 to 0.78) 10 0.963
12 months 0.10 (0.49 to 1.12) 15 0.19 (0.50 to 0.28) 25 0.288 0.39 (0.11 to 1.04) 9 0.21 (0.15 to 1.10) 9 0.798
24 months 0.54 (0.50 to 1.52) 12 0.18 (0.99 to 0.50) 20 0.071 1.38 (0.89 to 2.20) 9 0.11 (1.04 to 1.96) 9 0.101
All data are presented as median (interquartile range).
Mann-Whitney U test was used to determine P value.
Bold indicates a statistically significant difference between groups.
TABLE 4. Number of electrolyte disturbances
Before matching After matching
Standard Individualized P Standard Individualized P
Sodium 0 0 — 0 0 —
Potassium 1 (6.3%) 3 (9.4%) 1.000 1 (10%) 0 1.000
Calcium 0 3 (9.1%) 0.542 0 1 (10%) 1.000
Magnesium 1 (6.7%) 3 (10%) 1.000 0 1 (10%) 1.000
Phosphorus 4 (25%) 9 (28.1%) 1.000 2 (20%) 0 0.474
Chloride 2 (14.3%) 5 (16.7%) 1.000 1 (10%) 2 (20%) 0.582
Normal laboratory range: sodium 135–145mmol/L, potassium 3.5–5mmol/L, calcium 2.15–2.75mmol/L, magnesium 0.68–0.88mmol/L, phosphorus
1.00–2.05mmol/L, chloride 98–107mmol/L.
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(IQR: 29–128). Groups were comparable on all baseline character-
istics (Table 2).
After 24 months, median change in WFA SDS in the
standardized PN group was þ0.80 SD (0.12–1.40), whereas in
the individualized PN group, a median decrease in WFA SDS was
seen: 0.42 SD (0.17 to 0.47). The difference between these
groups did not reach statistical significance (P: 0.051). No statistical
differences were seen regarding change in HFA SDS or WFH SDS
between the 2 groups (Table 3).
The standardized PN group showed a median deficit of
17 calories/kg/day (27 to 3). This was significantly different
compared with the individualized PN group where a surplus of
1 calorie/kg/day per day was observed (18 to 12; P: 0.247).
No significant relationship between this calculated differ-
ence and change in WFA SDS was seen in both groups:
rt¼0.067, P: 0.851 for the standardized PN group and
rt¼ 0.048, P: 0.881 for the individualized PN group.
No statistical differences were observed between both groups
in any biochemical value.
DISCUSSION
This is the first study assessing the effects of standard-
ized and individualized PN formulations in a pediatric home PN
population. In this cohort, standardized PN mixtures in children
with chronic IF facilitated an increase in WFA SD score
whereas a decrease in WFA SDS was seen in the individualized
PN group. The same observation was made after age matching;
however, the difference between groups did not reach statistical
significance. No statistical differences in HFA Z-score and
WFH Z-score were observed between groups. Children receiv-
ing standardized PN mixtures did not have a higher number of
electrolyte or liver test abnormalities (including total and
conjugated bilirubin concentrations) compared with the individ-
ualized PN group.
The observed differences in potential confounders on growth
(i.e. gestational age and number of nights on PN) in our cohort
impose a possible risk of bias. To correct for the observed differ-
ences in potential confounders on growth, and reduce the risk of
bias, patients were age-matched, which resulted in an even distri-
bution of these potential confounders between groups. Of note,
patients included in the age-matched cohort were older than patients
in the original cohort with a minimum age of 2.5 years.
Children in our cohort receiving standardized PN mixtures
showed an average increase in WFA SDS over 24 months. This in
contrast to the group receiving individualized PN mixtures where a
decrease in WFA SDS was seen. No statistical difference was
observed for height gain or change in WFH SDS. The observed
change in WFA SDS cannot be explained by catch-up growth as the
standardized group was not lighter than the individualized PN group
at t minus 24 months. A possible explanation for the observed
decrease in WFA SDS in the individualized PN group could be the
lower gestational age in this group. Several studies report that
preterm children are at increased risk of impaired growth in
childhood (14,15). We did not see a statistically significant differ-
ence in the length of hospital admissions, as a surrogate marker for
disease activity, that could explain the observed decrease in WFA
SDS in the individualized PN group. As body composition was not
measured in this study, it should be emphasized that the observed
increase inWFA SDS in the standardized groupmight be because of
an undesirable increase in fat mass.
After age matching, we also observed an increase in WFA
SDS in the standardized group over 24 months and a decrease in the
individualized group. However, the observed differences did not
reach statistical significance.
The standardized PN group received 17 calories/kg/day less
than their calculated nutritional need via parenteral and enteral
nutrition combined. In the individualized PN group, the deficit was
4 calories/kg/day. These findings contradict the differences inWFA
SDS change described. The nutritional deficit did not statistically
correlate with WFA SDS change. These findings were also
observed in the age-matched cohort. Therefore, it seems reasonable
to exclude the deficit of provided (par)enteral nutrients as a reason
for the observed weight loss in this cohort. A possible explanation
could be the fact that the physician, in reaction to an increase in
WFH SDS, decreased the amount of prescribed calories. The
amount of oral intake was not noted in patient medical charts.
Furthermore, it is not known to which degree enterally provided
nutrients are absorbed. As such the observed discrepancy between
intake and weight gain could not be elucidated by the available data.
These findings imply that the group receiving standardized PN
mixtures had less ‘severe’ IF, which could explain the observed
difference in weight gain.
In recent studies in neonates, similar results were seen
regarding growth difference between infants receiving either indi-
vidualized or standardized PN mixtures. For example, Evering et al
found that premature infants (GA< 32 weeks) receiving standard-
ized PN mixtures had the highest cumulative weight gain compared
with infants receiving individualized or partially standardized
mixtures. Authors stated that (partially) standardized PN mixtures
were at least noninferior to individualized PN mixtures (16).
Regarding electrolyte abnormalities, we found no significant
differences between the 2 groups (entire cohort and age-matched
cohort). In both groups, no child needed to be admitted to hospital
becauseof electrolyte imbalances. Also, we did not see a difference
in the amount of abnormal liver tests or total and conjugated
bilirubin concentrations between the groups. This is in accordance
with several other studies, which also did not report an increase in
biochemical abnormalities in patients receiving standardized PN
mixtures (17,18). Micronutrient supplementation was similar in
both groups, and therefore, not analyzed.
Strength of this study is that this is the first study investigat-
ing the efficacy and safety of standardized and individualized PN
mixtures in home PN patients with a follow-up of 2 years. As stated
by the Cochrane handbook, adverse events can generally best be
assessed over a longer time period than most randomized clinical
trials report (19).
There are some methodological limitations to this study.
First, because of the retrospective character of this study, results
concerning nutritional intake should be interpreted with caution.
Second, the amount of included subjects is low and heterogeneous,
which is common in studies concerning the pediatric chronic IF
population because of the low prevalence (7,8). Additionally, the 2
groups of patients differ on the duration of PN therapy, age,
gestational age, and the amount of days PN is infused. Age
matching resulted in 2 comparable groups, however, the sample
size in the age-matched cohort is small, which reduced the power of
statistical tests in finding a significant difference. Finally, as
mentioned before, some possible confounders for weight gain could
not be taken into account.
Future studies should be done in an international collabora-
tion initiative, such as the European reference network on rare
inherited and congenital anomalies (ERNICA) or by the European
society for Paediatric Gastroenterology Hepatology and Nutrition
(ESPGHAN).
Studies should also assess the amount of oral caloric intake
and investigations of nutrient losses by bomb calorimetry to be able
to calculate the absorption of enteral nutrition. Furthermore, the
measurement of energy expenditure by indirect calorimetry could
provide useful data in assessing the role of underfeeding as a
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possible confounder. Lastly, data on body composition could give
interesting insights in the effects of both types of nutrition on the
child receiving home PN (20).
CONCLUSIONS
In children with chronic IF over 2.5 years of age, standard-
ized PN mixtures (with added micronutrients) show a comparable
effect on WFA, HFA, and WFH compared with individualized PN.
Furthermore, standardized PN mixtures are at least noninferior to
individualized PN mixtures in terms of basic biochemical abnor-
malities in a home PN cohort. Therefore, standardized PN mixtures
can be considered for patients with chronic IF older than 2,5 years
who have stable nutritional needs if the composition of this mixture
meets the nutritional need of the patient.
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